Investigating Treatments for Ovarian Cancer
Clinical Pre-screening Protocol for Ovarian Cancer
Recruiting
Observational Study
Ovarian Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 60 (estimated)
- Sponsor
- Allarity Therapeutics · Industry
Who this trial is looking for
This trial is looking for patients with ovarian cancer to see if their tumor tissue can help identify effective treatments. Participants will provide tissue samples to help understand how they might respond to different cancer drugs.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with epithelial ovarian cancer
- I have platinum-resistant disease, meaning my cancer has progressed within 6 months after platinum chemotherapy, or I cannot receive platinum-based treatment
- I have received no more than one previous treatment for my platinum-resistant or platinum-ineligible condition
- I have tumor tissue available for testing
You may not be able to join if
- I have platinum-refractory disease, meaning my cancer progressed during platinum chemotherapy
- I have another cancer, except for stage I or II cancers that my doctor says are cured
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivi…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with histological confirmed epithelia ovarian cancer
* Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.
* Patients have received no more than one prior…
Contacts